Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$114.02
0.400.35%
Last update: Nov 18, 11:53 AM
Comments
Loading...
Abivax Analyst Ratings and Price Targets | NASDAQ:ABVX | Benzinga
Abivax SA has a consensus price target of $88.73 based on the ratings of 15 analysts. The high is $176 issued by Wolfe Research on November 6, 2025. The low is $16 issued by Morgan Stanley on April 11, 2024. The 3 most-recent analyst ratings were released by Wolfe Research, Barclays, and Guggenheim on November 6, 2025, October 13, 2025, and October 10, 2025, respectively. With an average price target of $156 between Wolfe Research, Barclays, and Guggenheim, there's an implied 36.82% upside for Abivax SA from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wolfe Research
Barclays
Guggenheim
BTIG
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Abivax
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/06/2025 | 54.36% | Wolfe Research | → $176 | Initiates | → Outperform | |||
10/13/2025 | 24.54% | Barclays | → $142 | Initiates | → Overweight | |||
10/10/2025 | 31.56% | Guggenheim | $101 → $150 | Maintains | Buy | |||
10/07/2025 | 5.24% | BTIG | $112 → $120 | Maintains | Buy | |||
09/25/2025 | -0.02% | JMP Securities | $95 → $114 | Maintains | Market Outperform | |||
09/12/2025 | -11.42% | Morgan Stanley | $71 → $101 | Maintains | Overweight | |||
09/09/2025 | -1.77% | BTIG | $112 → $112 | Reiterates | Buy → Buy | |||
07/29/2025 | -1.77% | Piper Sandler | $70 → $112 | Maintains | Overweight | |||
07/23/2025 | -37.73% | Morgan Stanley | $12 → $71 | Upgrade | Equal-Weight → Overweight | |||
07/23/2025 | -38.61% | Piper Sandler | $42 → $70 | Maintains | Overweight | |||
07/23/2025 | -11.42% | LifeSci Capital | $45 → $101 | Maintains | Outperform | |||
07/23/2025 | -11.42% | Guggenheim | $50 → $101 | Maintains | Buy | |||
07/23/2025 | -16.68% | JMP Securities | $33 → $95 | Maintains | Market Outperform | |||
04/30/2025 | -71.06% | JMP Securities | $33 → $33 | Reiterates | Market Outperform → Market Outperform | |||
03/20/2025 | -89.48% | Morgan Stanley | → $12 | Assumes | → Equal-Weight | |||
03/18/2025 | -71.06% | Citizens Capital Markets | $33 → $33 | Reiterates | Market Outperform → Market Outperform | |||
01/10/2025 | -71.06% | JMP Securities | $33 → $33 | Reiterates | Market Outperform → Market Outperform | |||
12/04/2024 | -71.06% | JMP Securities | → $33 | Initiates | → Market Outperform | |||
07/29/2024 | -57.9% | Laidlaw & Co. | → $48 | Initiates | → Buy | |||
05/20/2024 | -62.29% | BTIG | → $43 | Initiates | → Buy | |||
04/29/2024 | -56.15% | Guggenheim | → $50 | Initiates | → Buy | |||
04/29/2024 | -63.16% | Piper Sandler | → $42 | Initiates | → Overweight | |||
04/11/2024 | -85.97% | Morgan Stanley | $15 → $16 | Maintains | Equal-Weight | |||
11/14/2023 | -82.46% | Leerink Partners | → $20 | Initiates | → Outperform | |||
11/14/2023 | -86.84% | Morgan Stanley | → $15 | Initiates | → Equal-Weight |
FAQ
What is the target price for Abivax (ABVX) stock?
The latest price target for Abivax (NASDAQ:ABVX) was reported by Wolfe Research on November 6, 2025. The analyst firm set a price target for $176.00 expecting ABVX to rise to within 12 months (a possible 54.36% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Abivax (ABVX)?
The latest analyst rating for Abivax (NASDAQ:ABVX) was provided by Wolfe Research, and Abivax initiated their outperform rating.
When was the last upgrade for Abivax (ABVX)?
The last upgrade for Abivax SA happened on July 23, 2025 when Morgan Stanley raised their price target to $71. Morgan Stanley previously had an equal-weight for Abivax SA.
When was the last downgrade for Abivax (ABVX)?
There is no last downgrade for Abivax.
When is the next analyst rating going to be posted or updated for Abivax (ABVX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abivax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abivax was filed on November 6, 2025 so you should expect the next rating to be made available sometime around November 6, 2026.
Is the Analyst Rating Abivax (ABVX) correct?
While ratings are subjective and will change, the latest Abivax (ABVX) rating was a initiated with a price target of $0.00 to $176.00. The current price Abivax (ABVX) is trading at is $114.02, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
